Bristol Myers Squibb Company $BMY Shares Sold by Hamilton Wealth LLC

Hamilton Wealth LLC lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 16.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,412 shares of the biopharmaceutical company’s stock after selling 17,071 shares during the quarter. Bristol Myers Squibb makes up approximately 1.0% of Hamilton Wealth LLC’s holdings, making the stock its 28th largest holding. Hamilton Wealth LLC’s holdings in Bristol Myers Squibb were worth $5,302,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter worth about $25,000. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. lifted its stake in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. Bayban acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Strong Q2 results and raised guidance: Bristol Myers reported adjusted EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion versus expectations of $11.74 billion. Revenue rose 5.7% year over year. Management raised 2026 EPS guidance to $6.75-$7.00 and revenue guidance to $49-$50 billion, both above Wall Street estimates. Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
• Positive Sentiment: Growth products are gaining momentum: Eliquis sales, along with newer medicines including Camzyos, Reblozyl, Opdivo Qvantig and Breyanzi, drove results. The growth portfolio now contributes roughly 60% of revenue, helping offset pressure from older products. Bristol-Myers Squibb Q2 2026 earnings call transcript
• Positive Sentiment: Several analysts raised targets: JPMorgan lifted its target from $67 to $73 and maintained an “overweight” rating, while Truist raised its target from $65 to $70 and reaffirmed “buy.” These revisions suggest analysts see additional upside following the earnings beat.
• Neutral Sentiment: Valuation is back in focus: Analysts note that BMY’s strong performance and recent rally have reduced the margin of safety, despite relatively attractive valuation and dividend support. RBC raised its target to $64 but retained a “sector perform” rating, implying the shares may remain range-bound. Bristol-Myers Squibb’s Catalyst Delays May Keep Stock Range-Bound, RBC Says
• Negative Sentiment: Pipeline timing and legacy declines remain risks: Delayed readouts or launches for Milvexian and Cobenfy, along with declines in older medicines such as Opdivo, could temper the growth outlook and postpone upcoming catalysts.
• Negative Sentiment: Bearish options activity: Traders purchased 44,620 put options, about 77% above typical daily volume, signaling increased hedging or speculation on downside risk.

Wall Street Analysts Forecast Growth

BMY has been the subject of several analyst reports. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday. Guggenheim reiterated a “buy” rating and issued a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday. Finally, UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $63.24.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $65.44 on Monday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market capitalization of $133.66 billion, a price-to-earnings ratio of 14.41, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $65.66. The company has a 50 day moving average price of $58.02 and a 200 day moving average price of $58.35.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the business earned $1.46 EPS. Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.88 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.